Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis - Top_Thought_Leaders - MDSpire

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

  • By

  • Kerri Miller

  • March 17, 2026

  • 4 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

  • by Kerri Miller

  • March 17, 2026

Related Content

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.